Therapeutic options for infections due to vancomycin-resistant enterococci

被引:7
|
作者
Wang, Jiun-Ling [1 ,2 ]
Hsueh, Po-Ren [1 ,3 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan
[2] I Shou Univ, Dept Internal Med, E Da Hosp, Kaohsiung, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 100, Taiwan
关键词
linezolid; review quinupristin-dalfopristin; treatment; vancomycin-resistant enterococci; INTENSIVE-CARE-UNIT; EUROPEAN MEDICAL-CENTERS; GRAM-POSITIVE BACTERIA; IN-VITRO ACTIVITY; LINEZOLID-RESISTANT; QUINUPRISTIN-DALFOPRISTIN; RISK-FACTORS; ANTIMICROBIAL SUSCEPTIBILITY; FAECIUM BACTEREMIA; 3RD-GENERATION CEPHALOSPORINS;
D O I
10.1517/14656560902811811
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Vancomycin-resistant enterococci (VRE) are an important cause of nosocomial infection occurring in critical care or immunocompromised patients. Objectives: To provide updated information about therapeutic options for VRE infection. Methods: MEDLINE, EMBASE, and the Cochrane Library were searched to identify in vitro susceptibility data of VRE isolates, randomized and non-randomized controlled trials, case series, and cohort studies of VRE therapy published before 31 July 2008. Results/conclusion: The updated in vitro susceptibility data for VRE show high resistance to ampicillin and aminoglycosides. Quinupristin-dalfopristin is limited by its lack of activity against vancomycin-resistant Enterococcus faealis and its musculoskeletal side effects. Emerging linezolid resistance has been reported to cause hospital spread and may be related to prolonged linezolid use. Quinupristin-dalfopristin resistance is usually linked to agricultural use of streptogramin. Nitrofurantoin and fosfomycin are alternatives in uncomplicated VRE urinary tract infection. Daptomycin and tigecycline have shown excellent potential for treating VRE infection.
引用
收藏
页码:785 / 796
页数:12
相关论文
共 50 条
  • [41] Economic burden of nosocomial infections caused by vancomycin-resistant enterococci
    Laura Puchter
    Iris Freya Chaberny
    Frank Schwab
    Ralf-Peter Vonberg
    Franz-Christoph Bange
    Ella Ebadi
    Antimicrobial Resistance & Infection Control, 7
  • [42] Risk of vancomycin-resistant enterococci bloodstream infection among patients colonized with vancomycin-resistant enterococci
    Kara, Ahu
    Devrim, Ilker
    Bayram, Nuri
    Katipoglu, Nagehan
    Kiran, Ezgi
    Oruc, Yeliz
    Demiray, Nevbahar
    Apa, Hursit
    Gulfidan, Gamze
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2015, 19 (01): : 58 - 61
  • [43] Vancomycin-resistant enterococci: eradication using vancomycin?
    J Van Prehn
    AM Stemerding
    HK Van Saene
    PE Spronk
    Critical Care, 18 (Suppl 1):
  • [44] VANCOMYCIN PRESCRIBING IN THE ERA OF VANCOMYCIN-RESISTANT ENTEROCOCCI
    POLK, R
    PHARMACOTHERAPY, 1995, 15 (05): : 682 - 683
  • [46] Central nervous system infections due to vancomycin-resistant enterococci: case series and review of the literature
    Wang, Jeffrey S.
    Muzevich, Katie
    Edmond, Michael B.
    Bearman, Gonzalo
    Stevens, Michael P.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 25 : 26 - 31
  • [47] Osteomyelitis attributable to vancomycin-resistant enterococci
    Holtom, PA
    Zamorano, D
    Patzakis, MJ
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2002, (403) : 38 - 44
  • [48] Vancomycin-resistant enterococci in turkeys and farmers
    vandenBogaard, AE
    Jensen, LB
    Stobberingh, EE
    NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (21): : 1558 - 1559
  • [49] Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci
    Wingler, Mary Joyce
    Patel, Neel R.
    King, S. Travis
    Wagner, Jamie L.
    Barber, Katie E.
    Stover, Kayla R.
    PHARMACY, 2021, 9 (04)
  • [50] Management of patients with vancomycin-resistant enterococci
    Morris, JG
    Roghmann, MC
    Schwalbe, R
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2000, 9 (01) : 10 - 16